In the last decade, the incidence of fungal infections has increased due to immunosuppressive chemotherapy and aggressive medical practices. [1] [2] [3] Antifungal therapies, however, are currently limited to a small number of compounds. Toxicity is an issue with treatments based on amphotericin B, 4) resistance is beginning to emerge as a problem with azoles, 5, 6) and poor oral absorption limits the use of candins. 7) Therefore, safe and orally available antifungal agents with novel modes of action are urgently needed.
We previously reported aminopiperidine derivatives which are novel antifungal compounds newly discovered in our laboratory. 8) These compounds exhibited potent inhibitory activities of ergosterol biosynthesis in the C-14 reduction catalyzed by Erg24p in Saccharomyces cerevisiae and Candida albicans. Ergosterol is a promising target for antifungals because three classes of ergosterol inhibitors, namely azoles, allylamines, and morpholines, have been already launched and are clinically available. [9] [10] [11] Among these antifungals, amorolfine exhibited antifungal activities by the inhibition of Erg24p, indicating this enzyme is validated as an antifungal target.
Here, we report on the in vitro and in vivo antifungal activities of aminopiperidine derivatives against clinically important fungi.
MATERIALS AND METHODS

Materials
The fungal strains used in this study were purchased from the American Type Culture Collection. The yeast strains were grown in Sabouraud Dextrose agar (SDA; Eiken Chemical Co., Ltd., Tokyo, Japan) and the filamentous strains were grown in Potato Dextrose agar (Eiken). In each in vitro assay, RPMI1640 media (Sigma-Aldrich, St. Louis, MO, U.S.A.) with 165 mM 3-(N-morpholino) propanesulfonic acid (pH 7.0; Nacalai Tesque Inc., Kyoto, Japan) was used. Compound 1a and 1b were synthesized in our laboratory. The structures of these compounds are shown in Fig. 1 . Fluconazole used in the in vitro assay was purchased from Sigma-Aldrich. In each in vitro assay, all the compounds were dissolved in dimethylsulfoxide (DMSO; Nakalai Tesque) and used at the final concentrations of DMSO less than 1%. In the in vivo study, Compound 1a and 1b were dissolved in 5% glucose (Wako Pure Chemical Industries, Ltd., Osaka, Japan) solution with 1% (v/v) lactic acid (SigmaAldrich) and a commercial preparation of fluconazole (Pfizer Japan Inc., Tokyo, Japan) was used.
Sterol Composition Analysis by Whole Cell Study The isolation of non-saponifiable lipids and the analysis of sterol composition by TLC were performed based on the methods reported previously. 8, 12, 13) The IC 50 value of each compound was determined as the concentration that showed 50% ergosterol synthesis inhibition compared with the ergosterol amount of the drug free control. All the TLC analyses were performed in duplicate or triplicate.
In Vitro Antifungal Susceptibility Testing An in vitro antifungal susceptibility test was performed by the micro dilution methods described in CLSI reference document M27-A3 14) and M38-A2, 15) with some modifications. Briefly, all the fungi were cultured with or without each drug at 30°C in RPMI1640 medium added with alamar blue (Biosource International Inc., Camarillo, CA, U.S.A.) as an indicator. The incubation time was determined for each strain in consideration of its growth speed (16-48 h). After incubation, an optical density of 570 nm was measured using a spectrophotometer (Wallac 1420 ARVOsx multi label counter; PerkinElmer Life and Analytical Inc., Waltham, MA, U.S.A.) and minimum inhibitory concentration (MIC) was determined by the concentration of the drug that showed 80% growth inhibition compared with that of the drug free control.
Time Aminopiperidine derivatives, Compound 1a and 1b, are novel small molecules that inhibit C-14 reduction catalyzed by Erg24p in ergosterol synthesis of Candida albicans. We evaluated the properties of the in vitro and in vivo activities of these compounds against pathogenic fungi and compared their activities with those of fluconazole. Compound 1a and 1b exhibited potent in vitro activities against clinically important fungi such as Candida species, including both of fluconazole-resistant strains of C. albicans and non-albicans Candida, Aspergillus fumigatus, and Cryptococcus neoformans. Against C. albicans, its mode of action was fungistatic. Furthermore, orally administered Compound 1b clearly prolonged the survival of infected mice in systemic lethal infection caused by C. albicans. These results suggest that aminopiperidine derivative is a promising lead compound for an orally available novel antifungal drug with a broad spectrum.
cans ATCC90028 were suspended in RPMI1640 medium with or without Compound 1a, Compound 1b, or fluconazole at a cell density of 1ϫ10 4 CFU/ml. The range of concentrations of each compound was 0.5 to 8 times of MIC against the tested strain. Samples were removed after incubation for 0, 3, 6 , and 24 h with gentle shaking at 30°C and spread on SDA plates. The number of viable cells in each sample was measured by counting the colonies on each plate after incubation at 30°C for 24 h. All the time-kill studies were conducted in triplicate.
Systemic Infection Five-week-old Slc:ddY female mice (Japan SLC Inc., Shizuoka, Japan) weighing 25 g were used. They were caged in groups of 10 and given food and water ad libitum. All the experiments with animals were carried out according to the guidelines provided by the Institutional Animal Care and Use Committee of Daiichi Pharmaceutical Co., Ltd. Cells of C. albicans grown overnight in SDA were collected and a fungal suspension was prepared with 0.1% Tween 80 (Wako) in saline. The mice were inoculated with 3.4ϫ10 5 cells via the tail vein. The drugs were administered orally three times daily for 1 d starting immediately postinoculation at one dose of 10 or 20 mg/kg for Compound 1a and 1b, and 1 mg/kg for fluconazole, respectively. In all the experiments, each group contained 10 mice and the control group received 0.2 ml of 5% glucose solution with 1% (v/v) lactic acid. The mortality of the mice was recorded for 14 d after infection.
Statistical Analysis A Kaplan-Meier analysis using a Log-rank test was performed to determine any statistical differences in the survival rates of mice treated with antifungal agents versus the control mice. Statistical significance was defined as pϽ0.05.
RESULTS
In Vitro Antifungal Activities Compound 1a and 1b
showed the inhibitory activities of ergosterol synthesis with IC 50 values of 0.063 and 0.016 mg/ml, respectively, which were consistent with the antifungal activities (MICs) in C. albicans (Table 1) . In Table 2 , the antifungal susceptibilities of these compounds and fluconazole against major fungi causing systemic mycoses are shown. Compound 1a exhibited potent antifungal activities with MICs of 0.125 to 8 mg/ml against all clinically important fungi, including Candida species, A. fumigatus, C. neoformans, and Trichosporon asahii. Moreover, MICs of Compound 1a and 1b against fluconazole-resistant strains of C. albicans and non-albicans Candida, such as C. glabrata and C. krusei, were lower than those of fluconazole, and no cross-resistance against these strains was observed. To obtain information of their mode of action, a time-kill study of aminopiperidine derivatives against C. albicans was conducted. As shown in Fig. 2 , Compound 1a and Compound 1b showed dose dependent growth inhibition in fungistatic manner. Furthermore, when treated at the concentration of more than 2MIC for 24 h, both of aminopiperidine derivatives inhibited the growth of C. albicans more strongly than fluconazole.
In Vivo Efficacy The in vivo antifungal activities of Compound 1a and 1b against C. albicans in a murine infection model were evaluated and compared to that of fluconazole. Compound 1a orally administered three times daily for 1 d at a dose of 10 and 20 mg/kg were not effective. On the other hand, Compound 1b orally administered showed the prolonged survival of infected mice in dose dependent manner. As shown in Fig. 3 , the efficacy of Compound 1b at the dose of 20 mg/kg was similar to that of fluconazole at a dose of 1 mg/kg (pϽ0.005 versus Control). MICs (mg/ml) were determined using CLSI microdilution methods with some modifications described in Materials and Methods.
DISCUSSION
In this study, we have presented the in vitro and in vivo activities of novel antifungals, aminopiperidine derivatives, inhibiting Erg24p in the ergosterol biosynthesis pathway.
These compounds exhibited potent in vitro antifungal activities against clinically important fungi causing systemic mycoses such as Candida spp. and Aspergillus fumigatus. Furthermore, it is reported that the target enzyme of these compounds, Erg24p, is highly conserved among various fungi, 16) and amorlfine targeting Erg24p is used as a topical antifungal agent against superficial mycosis.
10) Therefore, aminopiperidine derivatives might be expected to have a broad spectrum of antifungal activities against not only the pathogenic fungi causing systemic mycoses but also dermatophytes.
Recently, the increase in the number of fluconazole-resistant C. albicans isolates has become a clinical problem. 5, 6) Aminopiperidine derivatives exhibited potent antifungal activities against fluconazole-resistant strains of C. albicans. This antifungal spectrum is thought to be one of ideal properties as candidates for a new antifungal drug.
The antifungal activities of aminopiperidine derivatives against C. albicans ATCC90028 were fungistatic. However, Compound 1a and Compound 1b strongly inhibited its growth compared to fluconazole, one of the representative fungistatic antifungal agents.
Additionally, it is quite promising that orally administered Compound 1b prolonged the survival of mice infected by C. albicans. Instead of the lower MIC of Compound 1b than that of fluconazole, however, its in vivo efficacy was not superior to that of fluconazole partly due to its poor pharmacokinetic properties. The maximum concentration (C max ) of fluconazole in plasma when orally administered three times for 1 d at a dose of 1 mg/kg was nearly same to that of Compound 1b when administered in the same regimen at a dose of 20 mg/kg (C max of fluconazole and Compound 1b were 1.43 and 1.15 mg/ml, respectively). On the other hand, from only the data we have now, the reason why Compound 1a showed no in vivo efficacy cannot be clearly explained. The weak in vitro activity could be one of the reasons. In our pharmacokinetics study, however, it was observed that the small chemical modification of aminopiperidine derivatives caused the drastic decrease of their C max (data not shown), suggesting its insufficient concentration in plasma could be also one of the reasons. Furthermore, in the course of our recent pharmacokinetics/pharmacodynamics (PK/PD) study using other aminopiperidine derivatives, there was a compound which showed no in vivo efficacy instead of its strong in vitro activity (MIC) and enough concentration level in plasma (data not shown), indicating that in order to exhibit in vivo efficacy, many factors should be considered, such as in vitro activity, concentration in plasma, protein binding, solubility, tissue penetration, and so on. More detailed PK/PD study is needed and under estimation.
In conclusion, these data suggest that aminopiperidine derivative is a novel lead for an antifungal drug with a broad spectrum that is orally available. In order to obtain derivatives with an ideal pharmacokinetic profile, further chemical modifications and optimization are in progress. 
